Key result
Anticancer therapies, including vascular endothelial growth factor inhibitors, increase blood pressure, necessitating the new subspecialty of onco-hypertension to optimize management in cancer patients.
Why the study?
Clinical and laboratory evidence are lacking regarding optimal blood pressure control in patients with cancer and hypertension, including hypertension induced by anticancer therapy.
What is the optimal blood pressure management strategy for cancer patients with hypertension, particularly that induced by anticancer therapy?
What is the optimal blood pressure management strategy for cancer patients with hypertension, particularly that induced by anticancer therapy?
This review introduces the concept of onco-hypertension, emphasizing the need for targeted research on managing hypertension in the growing population of cancer survivors.
Rising cancer survivorship heightens hypertension burden in practice; leaves open optimal management strategies for this population.
Owing to aging populations, the prevalence of hypertension and associated cardiovascular events has been increasing worldwide. The morbidity and mortality due to cancer have also been increasing with aging populations. Several small-molecule inhibitors have been used in cancer therapy, which have a positive impact on the prognosis and survival of patients with cancer. Consequently, the number of cancer survivors with hypertension has been rapidly increasing. Anticancer therapy, including vascular endothelial growth factor inhibitors, increases blood pressure. However, both clinical and laboratory evidence are lacking regarding optimal blood pressure control in patients with hypertension with cancer. Here, we propose the concept of onco-hypertension, which is an evolving subspecialty focused on the complex pathophysiology of hypertension and cancer. In this review, we highlight blood pressure changes in cancer, hypertension induced by anticancer therapy, and optimal blood pressure management in patients with hypertension with cancer. In addition, we discuss needed studies to further establish this new onco-hypertension concept.
No takes yet. Share an insight, caveat, or question.
Kidoguchi et al. (2020) conducted a review in Hypertension and cancer. Anticancer therapy was evaluated. Anticancer therapies, including vascular endothelial growth factor inhibitors, increase blood pressure, necessitating the new subspecialty of onco-hypertension to optimize management in cancer patients.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: